Outlook Therapeutics, Inc. is a biopharmaceutical company focused on the development and commercialization of LYTENAVA™ (bevacizumab-vikg), an ophthalmic formulation approved for the treatment of wet age-related macular degeneration (AMD). The company generates revenue through the sale of LYTENAVA™, which has received regulatory approvals in the U.S. and Europe. Outlook Therapeutics primarily serves retina specialists and patients suffering from retinal diseases, operating in markets including Germany, Austria, and the UK.
